Reviewer’s report

Title: Adjuvant therapy for locally advanced renal cell cancer: A systematic review with meta-analysis

Version: 1 Date: 30 November 2010

Reviewer: Kazunori Haga

Reviewer’s report:

• Discretionary Revisions;
  P2, L4; Abstract; “adjuvant therapy setting in a renal cancer” is better?
  L13, 14; I2 # I2
  P8, L20 ; I2 # I2
  P9, L4 ; All three trials (1227 patients),
  P9, L10 ; Eight trials (1910 patients)
  -- same as P9, L20 ; All three trials (840 patients)

• Minor Essential Revisions;
  For the discussion; “all types of drug” could lead misunderstandings. This paper reviews most of the conventional adjuvant therapies other than molecular targeted therapy.
  And also, “adjuvant approaches studied are not improving” sounds like including all therapies such as molecular target therapy, even it states “studied”.
  So I think it will be better to arrange this statement with adding a little more explanations, however, it is good to explain the recent expectations for molecular target therapy in the last paragraph.
  Conclusion looks better, but it still sounds like too strong for this negative results.

• Major Compulsory Revisions;
  P2, L18; For Abstract; It is true this met analysis showed no benefits. However, some of them had significant results in the individual data and it sounds too strong to say “no adjuvant therapy can be recommended.” So I recommend to state this conclusion in a more mild expression.

Level of interest: An article whose findings are important to those with closely related research interests

Quality of written English: Acceptable

Statistical review: Yes, but I do not feel adequately qualified to assess the
Declaration of competing interests:

I declare that I have no competing interests.